Abstract
ROS1 inhibition in E-cadherin–deficient tumors leads to synthetic lethality, which could be exploited for the selective treatment of breast cancer patients.
- Copyright © 2018, American Association for the Advancement of Science
ROS1 inhibition in E-cadherin–deficient tumors leads to synthetic lethality, which could be exploited for the selective treatment of breast cancer patients.